New perspectives on the overactive bladder: Pharmokinetics and bioavailability

Urology

Volumn 60, Issue 5 SUPPL. 1, 2002, Pages 78-80

  Gupta, Suneel ^a   Sathyan, Gayatri ^a   Mori, Timothy ^a   Andersson, Karl Erik ^b   Staskin, David R ^b  

^a ALZA CORPORATION   (United States)

^b Building M11 ^*

Author keywords

[No Author keywords available]

Indexed keywords

KETOCONAZOLE; OXYBUTYNIN; TOLTERODINE;

BLADDER DISEASE; CONFERENCE PAPER; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; HYPERACTIVITY; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0036866163     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(02)01802-2     Document Type: Conference Paper

References (18)

1. Chapple C.R. Muscarinic receptor antagonists in the treatment of overactive bladder. Urology. 55:(suppl 5A):2000;33-46.
2. Ditropan tablets: Oxybutynin chloride tablets, in Physicians' Desk Reference. 53rd Ed. Montvale, NJ, Medical Economics, 1999, pp 511-512.
3. Ditropan XL tablets: Oxybutynin chloride extended-release tablets, in Physicians' Desk Reference. 56th Ed. Montvale, NJ, Medical Economics, 2002, pp 564-566.
4. Detrol tablets: Tolterodine tartrate tablets, in Physicians' Desk Reference. 55th Ed. Montvale, NJ, Medical Economics, 2001, pp 2600-2602.
5. Detrol LA tablets: Tolterodine tartrate extended-release capsule, in Physicians' Desk Reference. 56th Ed. Montvale, NJ, Medical Economics, 2002, pp 2801-2803.
6. Gupta S.K., Sathyan G. Pharmacokinetics of an oral once-a-day controlled-release oxybutynin formulation compared with immediate-release oxybutynin. J Clin Pharmacol. 39:1999;289-296.
7. Dmochowski R.R., Appell R.A. Advancements in pharmacologic management of the overactive bladder. Urology. 56:(suppl 1):2000;41-49.
8. Yarker Y.E., Goa K.L., Fitton A. Oxybutynin a review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in detrusor instability . Drugs Aging. 6:1995;243-262.
9. Kachur J.F., Peterson J.S., Carter J.P., et al. R and S enantiomers of oxybutynin pharmacological effects in guinea pigs bladder and intestine . J Pharmacol Exp Ther. 247:1988;867-872.
10. Sepracor Inc.: Sepracor Announces Successful Completion of a Phase II (S)-oxybutynin Trial. Media release: June 19, 2000. Available at: http://www.sepracor.com. Accessed February 20, 2002.
11. Sepracor Inc.: Sepracor Announces Initiation of a Phase III (S)-oxybutynin Sustained-release Study. Media release: June 20, 2001. Available at: http://www.sepracor.com . Accessed February 20, 2002.
12. Anderson R., Mobley D., Blank B., et al. Once daily controlled versus immediate release oxybutynin chloride for urge urinary incontinence. OROS Oxybutynin Study Group. J Urol. 161:1999;1809-1812.
13. Sathyan G., Hu W., Chancellor M.B., et al. Comparison of CYP3A4 inhibitor effects on the stereoselective pharmacokinetics of extended release oxybutynin and conventional oxybutynin. AAPS Pharm Sci. 1:1999;2056.
14. Van Kerrebroeck P.V., Kreder K., Jonas U., et al. Tolterodine once-daily superior efficacy and tolerability in the treatment of the overactive bladder . Urology. 57:2001;414-421.
15. Olsson B., Szamosi J. Multiple dose pharmacokinetics of a new once daily extended release tolterodine formulation versus immediate release tolterodine. Clin Pharmacokinetics. 40:2001;227-235.
16. Watson Pharmaceuticals, Inc.: Watson reports phase III study results for Oxytrol, its transdermal oxybutynin patch. Media release: October 26, 2001. Available at: http://www.watsonpharm.com. Accessed February 19, 2002.
17. Davila G.W., Daugherty C.A., Sanders S.W. A short-term, multicenter, randomized double-blind dose titration study of the efficacy and anticholinergic side effects of transdermal compared to immediate release oral oxybutynin treatment of patients with urge urinary incontinence. J Urol. 166:2001;140-145.
18. Enhance Pharmaceuticals, Inc.: Enhance UI information. Available at: http://www.feitech.com. Accessed February 20, 2002.